6-溴-3H-异苯并呋喃-1-酮 | 19477-73-7

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异香豆素
• 中文名称: 6-溴-3H-异苯并呋喃-1-酮
• 中文别名: 6-溴苯酞；6-溴-2-苯并呋喃-1(3H)酮
• 英文名称: 6-bromophthalide
• 英文别名: 6-bromoisobenzofuran-1(3H)-one；6-bromo-3H-isobenzofuran-1-one；6-bromo-2-benzofuran-1(3H)-one；6-bromo-1,3-dihydro-2-benzofuran-1-one；6-bromo-3H-2-benzofuran-1-one
• CAS: 19477-73-7
• 化学式: C₈H₅BrO₂
• mdl: MFCD03428561
• 分子量: 213.03
• InChiKey: BELKVKMBIAENSA-UHFFFAOYSA-N

物化性质

• 熔点：
  99.5 °C
• 沸点：
  362.4±42.0 °C(Predicted)
• 密度：
  1.742±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-3H-isobenzofuran-1-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-3H-isobenzofuran-1-one
CAS number: 19477-73-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5BrO2
Molecular weight: 213.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  4-溴邻苯二甲酸酐	4-bromophthalic anhydride	86-90-8	C8H3BrO3	227.014
  2-甲基-5-溴苯甲酸	5-bromo-2-methylbenzoic acid	79669-49-1	C8H7BrO2	215.046
  苯酞	2-benzofuran-1(3H)-one	87-41-2	C8H6O2	134.134
  5-溴-1,3-二氢-异苯并呋喃	5-bromo-1,3-dihydroisobenzofuran	220513-49-5	C8H7BrO	199.047
  6-氨基四氯苯酞	6-aminophthalide	57319-65-0	C8H7NO2	149.149
  间溴苯甲酸	m-bromobenzoic acid	585-76-2	C7H5BrO2	201.019
  4-溴-2-(羟基甲基)苄醇	(4-bromo-1,2-phenylene)dimethanol	171011-37-3	C8H9BrO2	217.062

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	6-bromo-3-hydroxyisobenzofuran-1(3H)-one	1225206-60-9	C8H5BrO3	229.03
  5-溴-2-甲酰基苯甲酸甲酯	methyl 5-bromo-2-formylbenzoate	1016163-89-5	C9H7BrO3	243.057
  ——	5-bromo-2-hydroxymethyl-benzoic acid	627909-55-1	C8H7BrO3	231.046
  ——	5-bromo-2-formylbenzoic acid	4785-52-8	C8H5BrO3	229.03
  ——	3,6-dibromoisobenzofuran-1(3H)-one	40125-50-6	C8H4Br2O2	291.927
  4-溴-2-(羟基甲基)苯甲酸	4-bromo-2-(hydroxymethyl)benzoic acid	670256-21-0	C8H7BrO3	231.046
  ——	4-bromo-2-((carboxymethoxy)methyl)benzoic acid	——	C10H9BrO5	289.082
  6-甲基-2-苯并呋喃-1(3H)-酮	6-methylphthalide	72985-23-0	C9H8O2	148.161
  6-羟基苯酞	6-hydroxyisobenzofuran-1(3H)-one	55104-32-0	C8H6O3	150.134
  ——	6-ethylisobenzofuran-1,3H-one	1286178-76-4	C10H10O2	162.188

反应信息

• 作为反应物：
  描述：

  6-溴-3H-异苯并呋喃-1-酮 在 sodium hydroxide 、 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 三氟化硼乙醚 、 sodium methylate 、 4-甲基苯磺酸吡啶 、 对甲苯磺酸 、 三氟乙酸酐 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 9-bromo-11-methoxy-2-(oxan-2-yloxymethyl)-6,11-dihydrobenzo[c][1]benzoxepine
  参考文献：
  名称：

  新系列的抗过敏药。二。新的6,11-二氢二苯并[b，e]氧杂环丁烷羧酸衍生物的合成及活性。

  摘要：

  开发了制备多功能的6,11-二氢二苯并[b，e]氧杂环丁烷的新方法。确定了有希望的口服活性抗过敏药KW-4994（1）的结构要求。C-2处的羧基对于增强1的抗过敏活性至关重要。在C-9处引入1的溴原子可以延长亲本的作用时间。在1的衍生物之一中观察到抗血小板活性，这是该系列化合物的新药理特性。

  DOI：

  10.1248/cpb.39.2729
• 作为产物：
  描述：

  苯酞 在 N-溴代丁二酰亚胺(NBS) 、 硫酸 作用下， 以 溶剂黄146 为溶剂， 反应 120.0h， 以62%的产率得到6-溴-3H-异苯并呋喃-1-酮
  参考文献：
  名称：

  异构纯四甲基罗丹明电压报告器

  摘要：

  我们展示了基于异构纯四甲基罗丹明的新型荧光电压指示剂系列的设计、合成和应用。这些新型罗丹明电压报告器 (RhoVR) 使用光诱导电子转移 (PeT) 作为电压传感的触发器，在可见光谱的绿色到橙色区域显示激发和发射曲线，表现出对膜电位变化的高灵敏度（高达 47 % ΔF/F 每 100 mV），并采用源自肌氨酸的叔酰胺，这有助于膜定位，同时简化了电压传感器的合成路线。 RhoVR 染料中最灵敏的 RhoVR 1 在罗丹明芳环的 5' 位具有甲氧基取代的二乙基苯胺供体和亚苯基亚乙烯基分子线，在基于 PeT 的红移电压传感器中表现出迄今为止最高的电压灵敏度，并且与基于绿色荧光蛋白的指示剂同时成像兼容。分子线电压指示剂中基于肌氨酸的叔酰胺可防止染料内化，并且 5' 取代的电压指示剂表现出改善的电压灵敏度，这一发现应该广泛适用于其他类型的基于 PeT 的电压敏感荧光团。

  DOI：

  10.1021/jacs.6b05672

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Access to β-Keto Esters by Palladium-Catalyzed Carbonylative Coupling of Aryl Halides with Monoester Potassium Malonates
  作者：Signe Korsager、Dennis U. Nielsen、Rolf H. Taaning、Troels Skrydstrup

  DOI：10.1002/anie.201304072

  日期：2013.9.9

  New tricks for an old dog: The Pd‐catalyzed carbonylative α‐arylation of monoethyl potassium malonates with aryl bromides and reactive aryl chlorides provides a simple and direct route to aryl β‐ketoesters. Because only stoichiometric amounts of carbon monoxide are employed, the method is ideal for the introduction of carbon isotopes into more complex structures.

  老狗的新招数：丙二酸单乙酯钾的Pd催化羰基α-芳基化与芳基溴化物和反应性芳基氯化物的合成提供了一条简单而直接的途径制备芳基β-酮酸酯。由于仅使用化学计量的一氧化碳，因此该方法非常适合将碳同位素引入更复杂的结构中。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• PROTOZOAN PARASITE GROWTH INHIBITORS
  申请人：Northeastern University

  公开号：US20150259331A1

  公开（公告）日：2015-09-17

  Compounds and methods for inhibiting growth of a protozoan parasite. Methods of treating a protozoan parasite infection in a subject by administering a therapeutically effective amount of a compound as disclosed herein. The compounds and methods can be used to inhibit growth of protozoan parasites such as Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., and Plasmodium spp.

  用于抑制原生动物寄生虫生长的化合物和方法。通过向主体施用如本文所述的治疗有效量的化合物来治疗原生动物寄生虫感染的方法。这些化合物和方法可用于抑制如非洲锥虫、克鲁兹锥虫、利什曼原虫属和疟原虫属等原生动物寄生虫的生长。
• 蛋白质精氨酸甲基转移酶5(PRMT5)的抑制剂、其药学产品及其方法
  申请人：南京药石科技股份有限公司

  公开号：CN111825656B

  公开（公告）日：2023-03-31

  本发明提供式(I)的PRMT5抑制剂，其中R1是非氢单价基团；W是直接键或‑NH‑；T、U和V彼此独立地选自C和N；R2是H或卤素；m是1或2；X是碳、氮或氧；Y是C或N；Z是直接键或碳；R3是H、非氢单价基团、氧代基、二价螺环形成基团或二价桥形成基团；n是1或2；并且代表单键或双键。还提供包含PRMT5抑制剂的药物产品及其在治疗增殖性病症例如癌症、代谢病症、血液病症、自身免疫疾病和炎性疾病中的用途。